These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15672489)

  • 21. Imatinib: as adjuvant therapy for gastrointestinal stromal tumor†: profile report.
    Sanford M; Scott LJ
    BioDrugs; 2011 Jun; 25(3):191-2. PubMed ID: 21627342
    [No Abstract]   [Full Text] [Related]  

  • 22. Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy.
    Srinivas U; Barwad A; Pubbaraju SV
    Br J Haematol; 2014 Jun; 165(5):583. PubMed ID: 24456122
    [No Abstract]   [Full Text] [Related]  

  • 23. Control of aggressive fibromatosis by treatment with imatinib mesylate: a step forward?
    Ravaioli A; Nicoletti S; Tamburini E; Papi M
    J Cancer Res Clin Oncol; 2009 Feb; 135(2):325-6. PubMed ID: 18825412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients.
    Katagiri S; Umezu T; Ohyashiki JH; Ohyashiki K
    Br J Haematol; 2013 Jan; 160(2):269-71. PubMed ID: 23116058
    [No Abstract]   [Full Text] [Related]  

  • 25. Imatinib buys time for brain after stroke.
    Rieckmann P
    Nat Med; 2008 Jul; 14(7):712-3. PubMed ID: 18607366
    [No Abstract]   [Full Text] [Related]  

  • 26. STI-571 in chronic myelogenous leukaemia.
    Tsao AS; Kantarijian H; Talpaz M
    Br J Haematol; 2002 Oct; 119(1):15-24. PubMed ID: 12358949
    [No Abstract]   [Full Text] [Related]  

  • 27. Imatinib mesylate in the treatment of gastrointestinal stromal tumour.
    Steinert DM; McAuliffe JC; Trent JC
    Expert Opin Pharmacother; 2005 Jan; 6(1):105-13. PubMed ID: 15709888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
    Smith BD
    J Natl Cancer Inst; 2011 Apr; 103(7):527-9. PubMed ID: 21422404
    [No Abstract]   [Full Text] [Related]  

  • 29. After 30 years of laboratory work, a quick approval for STI571.
    Arnold K
    J Natl Cancer Inst; 2001 Jul; 93(13):972. PubMed ID: 11438558
    [No Abstract]   [Full Text] [Related]  

  • 30. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.
    Palmberg E; Johnsen JI; Paulsson J; Gleissman H; Wickström M; Edgren M; Ostman A; Kogner P; Lindskog M
    Int J Cancer; 2009 Mar; 124(5):1227-34. PubMed ID: 19058199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response of histiocytoses to imatinib mesylate: fire to ashes.
    Janku F; Amin HM; Yang D; Garrido-Laguna I; Trent JC; Kurzrock R
    J Clin Oncol; 2010 Nov; 28(31):e633-6. PubMed ID: 20733125
    [No Abstract]   [Full Text] [Related]  

  • 33. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
    Jabbour E; Cortes J; Kantarjian H
    Oncology (Williston Park); 2007 May; 21(6):653-62; discussion 663-4, 667-8. PubMed ID: 17564324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical practice guidelines in gastrointestinal stromal tumours (GEIS): update 2008].
    Poveda A; Artigas V; Casado A; Cervera J; García Del Muro X; Antonio López-Guerrero J; López-Pousa A; Maurel J; Ortega L; Ramos R; Romero I; Safont MJ; Martín J;
    Cir Esp; 2008 Oct; 84 Suppl 1():1-21. PubMed ID: 19087862
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacotherapy of gastrointestinal stromal tumours.
    Eisenberg BL; von Mehren M
    Expert Opin Pharmacother; 2003 Jun; 4(6):869-74. PubMed ID: 12783584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy.
    Rosário Cavalheiro Rde C; Vicari P; Maria Morselli F; Ommati LV; Frazão Rosa Fde O; Rodrigues Oliveira JS
    Am J Hematol; 2006 Jan; 81(1):76-7. PubMed ID: 16369975
    [No Abstract]   [Full Text] [Related]  

  • 37. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
    Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G
    Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110
    [No Abstract]   [Full Text] [Related]  

  • 38. Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses.
    Utikal J; Ugurel S; Kurzen H; Erben P; Reiter A; Hochhaus A; Nebe T; Hildenbrand R; Haberkorn U; Goerdt S; Schadendorf D
    Arch Dermatol; 2007 Jun; 143(6):736-40. PubMed ID: 17576939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Molecular targets in colon cancer].
    Borner MM
    Ther Umsch; 2006 Apr; 63(4):243-8. PubMed ID: 16689454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts.
    Silberman S; Joensuu H
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S66-9. PubMed ID: 12528775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.